Research ArticleClinical Investigation
Open Access
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M. Catafau and Ayse T. Kendi
Journal of Nuclear Medicine May 2023, 265077; DOI: https://doi.org/10.2967/jnumed.122.265077
Phillip H. Kuo
1University of Arizona, Tucson, Arizona;
Don C. Yoo
2Warren Alpert Medical School of Brown University, Providence, Rhode Island;
Ryan Avery
3Northwestern University, Evanston, Illinois;
Marc Seltzer
4Geisel School of Medicine at Dartmouth, Hanover, New Hampshire;
Jeremie Calais
5Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
James Nagarajah
6Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands;
Wolfgang A. Weber
7TUM School of Medicine, Technical University of Munich, Munich, Germany;
Wolfgang P. Fendler
8Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
Michael S. Hofman
9Cancer Imaging, Prostate Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
10Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
Bernd J. Krause
11Rostock University Medical Center, Rostock, Germany;
Marcia Brackman
12Novartis Pharmaceuticals Corporation, Indianapolis, Indiana;
Euloge Kpamegan
13Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Samson Ghebremariam
13Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;
Taylor Benson
14Novartis Pharmaceuticals Corporation, St. George, Utah;
Ana M. Catafau
15Advanced Accelerator Applications, Geneva, Switzerland; and
Ayse T. Kendi
16Mayo Clinic, Rochester, Minnesota
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M. Catafau, Ayse T. Kendi
Journal of Nuclear Medicine May 2023, 265077; DOI: 10.2967/jnumed.122.265077
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy
Phillip H. Kuo, Don C. Yoo, Ryan Avery, Marc Seltzer, Jeremie Calais, James Nagarajah, Wolfgang A. Weber, Wolfgang P. Fendler, Michael S. Hofman, Bernd J. Krause, Marcia Brackman, Euloge Kpamegan, Samson Ghebremariam, Taylor Benson, Ana M. Catafau, Ayse T. Kendi
Journal of Nuclear Medicine May 2023, 265077; DOI: 10.2967/jnumed.122.265077